Despite their blockbuster status and distinction as the world's most widely prescribed class of drugs, statins may not be the best option for all patients with elevated low density lipoprotein (LDL) cholesterol levels.
To no surprise, Gilead Sciences' Harvoni and Sovaldi were the top-selling infectious disease products in 2015.
The goal is to develop medications that move beyond the high-toxicity and low-efficacy profiles of older drugs.
Even as Gilead prepares to launch a third hepatitis-C product, drugs offering better antimicrobial resistance are angling for their own moments in the spotlight.
AbbVie's Humira is the top selling autoimmune drug in 2015, bringing in $10.6 billion in sales in the U.S. alone.
The bar for market success has been set high for baricitinib.
Drugmakers are working toward developing drugs in lupus, celiac disease, and other conditions that have rarely captured their attention in the past.
The biotech company is working with the foundation and Brown University to develop new regimens for the socially stigmatized condition.
Roche's Rituxan generated $7.3 billion in sales in 2015, making it the top-selling orphan drug.
With drugs treating rare diseases priced at sky-high levels, can the healthcare system shoulder the financial burden they impose?